Smooth muscle antibodies and cryoglobulinemia are associated with advanced liver fibrosis in Brazilian hepatitis C virus carriers

ABSTRACT

Cryoglobulinemia and non-organ-specific-autoantibody are biomarkers of autoimmunity of the chronic infection caused by hepatitis C virus (HCV). In this work, we report the association between the presence of smooth muscle antibodies (SMA) and cryoglobulinemia and chronic liver disease in HCV carriers. Sixty-five untreated HCV patients, 38 women and 27 men were included in this study. Cryoglobulinemia was tested by cryoprecipitation, SMA by indirect fluorescent antibody test, and liver fibrosis and hepatocellular inflammation activity was investigated by histology of liver biopsy using the METAVIR score. The prevalence of SMA in the patients was 33.8% and cryoglobulinemia was demonstrated in 36.9% patients. Cryoglobulinemia and SMA seropositivity was associated with advanced fibrosis (p < 0.05). The presence of SMA and cryoglobulinemia was not associated with hepatocellular inflammation activity, age, carrier gender or HCV genotype. We concluded that liver biopsy should be recommended for HCV carriers that are seropositive for SMA or cryoglobulinemia.

Keywords: hepatitis C; muscle; smooth; antibody specificity; cryoglobulins; liver diseases.

INTRODUCTION

Patients chronically infected by hepatitis C virus (HCV) present various immune-mediated phenomena mainly due to B lymphocyte dysfunction as mixed cryoglobulinemia and non-organ-specific autoantibodies (NOSAs) production. Although cryoglobulinemia has been associated with vasculitis of small and medium-size vessels and glomerulonephritis, the involvement of NOSAs in the immunopathology of hepatitis C is not completely understood. However, the presence of smooth muscle antibodies (SMA) has been reported to be higher in cryoglobulinemic HCV carriers, whereas cryoglobulinemia has been associated with advanced liver fibrosis and poor response to antiviral therapy with interferon-α.

In this study we report the association between SMA, cryoglobulinemia and liver fibrosis in untreated Brazilian HCV carriers.

PATIENTS AND METHODS

Patients

Sixty-five consecutive untreated HCV carriers (38 women and 27 men), with a mean age of 51.3 ± 13.9 years (ranging from 20 to 67 years), from two hepatitis reference centers in Salvador (Bahia, Brazil) were included in this study. They tested positive for serum anti-HCV antibodies using the META VIR score. The prevalence of SMA in the patients was 33.8% and cryoglobulinemia was demonstrated in 36.9% patients. Cryoglobulinemia and SMA seropositivity was associated with advanced fibrosis (p < 0.05). The presence of SMA and cryoglobulinemia was not associated with hepatocellular inflammation activity, age, carrier gender or HCV genotype. We concluded that liver biopsy should be recommended for HCV carriers that are seropositive for SMA or cryoglobulinemia.

Keywords: hepatitis C; muscle; smooth; antibody specificity; cryoglobulins; liver diseases.

INTRODUCTION

Patients chronically infected by hepatitis C virus (HCV) present various immune-mediated phenomena mainly due to B lymphocyte dysfunction as mixed cryoglobulinemia and non-organ-specific autoantibodies (NOSAs) production. Although cryoglobulinemia has been associated with vasculitis of small and medium-size vessels and glomerulonephritis, the involvement of NOSAs in the immunopathology of hepatitis C is not completely understood. However, the presence of smooth muscle antibodies (SMA) has been reported to be higher in cryoglobulinemic HCV carriers, whereas cryoglobulinemia has been associated with advanced liver fibrosis and poor response to antiviral therapy with interferon-α.

In this study we report the association between SMA, cryoglobulinemia and liver fibrosis in untreated Brazilian HCV carriers.

PATIENTS AND METHODS

Patients

Sixty-five consecutive untreated HCV carriers (38 women and 27 men), with a mean age of 51.3 ± 13.9 years (ranging from 20 to 67 years), from two hepatitis reference centers in Salvador (Bahia, Brazil) were included in this study. They tested positive for serum anti-HCV antibodies using the META VIR score. The prevalence of SMA in the patients was 33.8% and cryoglobulinemia was demonstrated in 36.9% patients. Cryoglobulinemia and SMA seropositivity was associated with advanced fibrosis (p < 0.05). The presence of SMA and cryoglobulinemia was not associated with hepatocellular inflammation activity, age, carrier gender or HCV genotype. We concluded that liver biopsy should be recommended for HCV carriers that are seropositive for SMA or cryoglobulinemia.

Keywords: hepatitis C; muscle; smooth; antibody specificity; cryoglobulins; liver diseases.
The histological abnormalities in liver biopsy were classified in accordance with the META VIR system: F0, no fibrosis; F1, portal fibrosis without septa; F2, few septa; F3, numerous septa without cirrhosis; and F4, cirrhosis. Necroinflammatory activity was graded on a scale of A0-A3, corresponding A0 to no histological activity; A1, mild activity; A2, moderate activity; and A3, severe activity.

Cryoglobulinemia and SMA

Cryoglobulin was investigated using both tube and gel cryoprecipitation. Smooth muscle IgG antibodies were tested by indirect fluorescent antibody test using antigenic substrates of rodent rat liver–kidney–stomach sections and sera diluted at 1:40.

Statistical analysis

The association between two or more categorical groups was analyzed by the Exact Fisher test or the chi-square test, using the statistical software SPSS™ version 16.0 for Windows. A p-value < 0.05 was considered significant.

RESULTS

Varied degrees of fibrosis were observed in the HCV carriers. Forty-four out of 65 (67.7%) carriers had mild to moderate fibrosis (F1-F2), 16 out of 65 (32.3%) had advanced fibrosis (F3) and five (7.7%) had cirrhosis (F4). No inflammatory activity (A0) was observed in 13 HCV carrier. Seven of them had a mild inflammatory activity (A1), 30 presented a moderate activity (A2) and in only two individuals it was severe.

Smooth muscle antibodies were detected in 22 out of 65 (33.8%) HCV carriers and cryoglobulinemia was found in 24 out of 65 (36.9%) patients. Advanced liver fibrosis (F3-F4) was associated with the presence of smooth muscle antibodies (Fisher exact test, p = 0.048), and progression to advanced liver fibrosis with the presence of cryoglobulinemia (chi-square test, p = 0.031) (Figure 1).

Neither smooth muscle antibodies nor cryoglobulinemia was associated with hepatocellular inflammatory activity, age, carrier gender or any HCV genotype.

DISCUSSION

In this study, we demonstrated the association of SMA and cryoglobulinemia with liver fibrosis in Brazilian HCV carriers. Smooth muscle antibodies are immunoglobulins that react with filaments of the cytoskeleton, which are represented by microfilaments (actin and vinculin), intermediate filaments (vimentin and desmin) and microtubules (tubulin). Although these autoantibodies are more commonly detected in autoimmune hepatitis, mainly anti-actin antibodies, they may also be found in low titers and varied prevalence in normal individuals and in patients presenting different infections, cancer and systemic autoimmune diseases. Smooth muscle antibodies are frequently detected in sera of HCV carriers as previously reported by several authors, with a prevalence varying from 10% to 55%. The prevalence of SMA found in HCV carriers in this work was in accordance with the findings of a previous Brazilian study and also in accordance with the reports of hepatitis C studies performed in different countries.

Hepatic fibrosis is caused by a complex immune mechanism, influenced by genetic and environmental factors, which involves cytokines as TGF-beta, angiotensin II and leptin. Inflammatory cells as polymorphonuclear cells and lymphocytes, and also activated hepatic stellate cells, portal fibroblasts and myofibroblasts participate in this process that culminates with excessive secretion of matrix proteins including collagen. Our results found the association between SMA seropositivity and advanced fibrosis (F3-F4) that may be an additional evidence of the involvement of the Th2 immune response in the active fibrogenesis as previously revised. The association between SMA and advanced fibrosis was also reported in a recent study performed with French HCV carriers, which also demonstrated an association between the presence of SMA and hepatocellular necrosis and inflammation, a finding that was not verified in our work. Such a divergence related to hepatic fibrosis was observed in these studies in comparison to our results.
necroinflammation may be caused by ethnic difference in the populations studied or by difference in the genetic background of the HCV carriers investigated. This possibility may be supported by the association of smooth muscle antibodies with HLA A1-B8-DR3 haplotype. Nevertheless, the involvement of molecular homology between HCV proteins and human self-antigens in the production of SMA has been documented.

Cryoglobulinemia is the main extra-hepatic manifestation of chronic hepatitis C, which is caused by a dysfunction of B-lymphocyte and is immunologically characterized by a cryoprecipitable immune complex formed by rheumatoid factor and IgG antibodies linked to HCV core antigen. Its prevalence varies from 29% to 54% in HCV carriers, and has been clinically associated with leg ulcers, vasculitis, palpable purple skin lesions and glomerulonephritis. The statistically significant association between CM positivity and advanced fibrosis in our study was in agreement with results of a Greek study that reported an association between cryoglobulinemia and staging score of chronic HCV infection. Nevertheless, this association is still controversial and need more studies to elucidate and establish the link between these two immunopathological aspects of chronic hepatitis C.

We concluded that liver histology should be performed in untreated HCV carriers that are seropositive for either smooth muscle antibodies or cryoglobulinemia.

REFERENCES